Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017-18 influenza season

Autor: Mario Carballido-Fernández, Ainara Mira-Iglesias, Germán Schwarz-Chavarri, Miguel Tortajada-Girbés, Javier Díez-Domingo, Respiratory Viruses Disease, F. Xavier López-Labrador, Juan Mollar-Maseres, Joan Puig-Barberà, Víctor Baselga-Moreno
Přispěvatelé: UCH. Departamento de Medicina y Cirugía, Producción Científica UCH 2019, UCH. Departamento de Medicina (Extinguido)
Rok vydání: 2019
Předmět:
Male
medicine.medical_specialty
Influenza vaccine
viral infections
Influenza season
hospitalisations
influenza virus
Influenza A Virus
H1N1 Subtype
Influenza - Vaccination - Spain - Valencia (Autonomous Community)
Ancianos - Vacunación - España - Comunidad Valenciana
Vaccination status
Virology
Internal medicine
vaccine
Epidemiology
Influenza
Human
Medicine
Elderly people
Humans
Aged
Influenza immunisation
Gripe - Vacunación - España - Comunidad Valenciana
business.industry
Influenza A Virus
H3N2 Subtype
Research
Vaccination
Public Health
Environmental and Occupational Health
Influenza a
Middle Aged
Hospitalization
Influenza B virus
Treatment Outcome
Influenza Vaccines
Spain
surveillance
Female
epidemiology
Seasons
business
influenza
Older people - Vaccination - Spain - Valencia (Autonomous Community)
Sentinel Surveillance
Zdroj: CEU Repositorio Institucional
Fundación Universitaria San Pablo CEU (FUSPCEU)
Eurosurveillance
Popis: Introduction Influenza immunisation is recommended for elderly people each season. The influenza vaccine effectiveness (IVE) varies annually due to influenza viruses evolving and the vaccine composition. Aim To estimate, in inpatients ≥ 60 years old, the 2017/18 trivalent IVE, overall, by vaccine type and by strain. The impact of vaccination in any of the two previous seasons (2016/17 and 2015/16) on current (2017/18) IVE was also explored. Methods This was a multicentre prospective observational study within the Valencia Hospital Surveillance Network for the Study of Influenza and Respiratory Viruses Disease (VAHNSI, Spain). The test-negative design was applied taking laboratory-confirmed influenza as outcome and vaccination status as main exposure. Information about potential confounders was obtained from clinical registries and/or by interviewing patients; vaccine information was only ascertained by registries. Results Overall, 2017/18 IVE was 9.9% (95% CI: −15.5 to 29.6%), and specifically, 48.3% (95% CI: 13.5% to 69.1%), −29.9% (95% CI: −79.1% to 5.8%) and 25.7% (95% CI: −8.8% to 49.3%) against A(H1N1)pdm09, A(H3N2) and B/Yamagata lineage, respectively. For the adjuvanted and non-adjuvanted vaccines, overall IVE was 10.0% (95% CI: −24.4% to 34.9%) and 7.8% (95% CI: −23.1% to 31.0%) respectively. Prior vaccination significantly protected against influenza B/Yamagata lineage (IVE: 50.2%; 95% CI: 2.3% to 74.6%) in patients not vaccinated in the current season. For those repeatedly vaccinated against influenza A(H1N1)pdm09, IVE was 46.4% (95% CI: 6.8% to 69.2%). Conclusion Our data revealed low vaccine effectiveness against influenza in hospitalised patients ≥60 years old in 2017/18. Prior vaccination protected against influenza A(H1N1)pdm09 and B/Yamagata-lineage.
Databáze: OpenAIRE
Externí odkaz: